













rethink PCR


- normalization
- data analysis
- assay validation



outline part normalization

- problem
- multiple reference gene normalization
 - geNorm
 - other methods
- expressed Alu repeat normalization





normalization: what's the problem?

- gene-specific (biological) variation
- non-specific (technical) variation
 - RNA extraction yield
 - RNA quantity & quality
 - RT efficiency
 - PCR efficiency





normalization: what's the solution (part I)?

Genes and Immunity (2005) 6, 279–284
© 2005 Nature Publishing Group All rights reserved 1466-4879/05 \$30.00



www.nature.com/gene

Real-time RT-PCR normalisation; strategies and considerations

J Huggett^{1,2}, K Dheda^{1,2,3}, S Bustin⁴ and A Zumla^{1,2}


¹Centre for Infectious Diseases and International Health, University College London, London, UK; ²Royal Free Medical School, London, UK; ³Department of Thoracic and HIV Medicine, Royal Free Hospital, London, UK; ⁴Centre for Academic Surgery, Barts and the London, Queen Mary's School of Medicine and Dentistry, London, UK

Real-time RT-PCR has become a common technique, no longer limited to specialist core facilities. It is in many cases the only method for measuring mRNA levels of vivo low copy number targets of interest for which alternative assays either do not exist or lack the required sensitivity. Benefits of this procedure over conventional methods for measuring RNA include its sensitivity, large dynamic range, the potential for high throughout as well as accurate quantification. To achieve this, however, appropriate normalisation strategies are required to control for experimental error introduced during the multistage process required to extract and process the RNA. There are many strategies that can be chosen; these include normalisation to sample size, total RNA and the popular practice of measuring an internal reference or housekeeping gene. However, these methods are frequently applied without appropriate validation. In this review we discuss the relative merits of different normalisation strategies and suggest a method of validation that will enable the measurement of biologically meaningful results.

Genes and Immunity (2005) 6, 279–284. doi:10.1038/sj.gene.6364190

Published online 7 April 2005





normalization: what's the solution (part I)?

- sampling size (number of cells, volume or mass of the sample)
 - reproducible extraction yields
 - not always possible (e.g. microdissected tissue)
- total RNA amount
 - not always possible (e.g. embryo)
 - quality (inhibitors)
 - cDNA synthesis efficiency is not taken into account
 - total RNA (rRNA) is not always representative of the mRNA fraction
- spiking (alien RNA)
 - corrects for enzymatic efficiency differences
 - not assumption-free (equal input template)





normalization: what's the solution (part I)?





Figure 1 Processes required to generate a real time RT-PCR result. Black arrows indicate points, which should be considered for a good normalisation strategy.





normalization: what's the solution (part II)?

- reference genes
 - most popular
 - capture most variation
- attention!
 - reference genes (might) vary in expression
 - until recently, non-validated reference genes were used (assuming stable expression)
- normalization against 3 or more validated reference genes is considered as the most appropriate and universally applicable method
 - 3rd London qPCR Symposium (April 2005)
 - which genes?
 - how to do the calculations?





normalisation: our geNorm solution

- framework for qPCR gene expression normalisation using the reference gene concept:
 - quantified errors related to the use of a single reference gene (> 3 fold in 25% of the cases; > 6 fold in 10% of the cases)
 - developed a robust algorithm for assessment of expression stability of candidate reference genes
 - proposed the geometric mean of at least 3 reference genes for accurate and reliable normalisation
 - Vandesompele et al., Genome Biology, 2002


Research

Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes Jo Vandesompele, Katleen De Preter, Filip Pattyn, Bruce Poppe, Nadine Van Roy, Anne De Paepe and Frank Speleman



rethink your reference genes

quantitative RT-PCR analysis of candidate reference genes







geNorm expression stability parameter

pairwise variation V (between 2 genes)


	gene A	gene B			
sample 1	a1	b1	log2(a1/b1)		
sample 2	a2	b2	log2(a2/b2)		
sample 3	a3	b3	log2(a3/b3)		
	•••		•••		
sample n	an	bn	log2(an/bn)		
			'		
standard deviation = V					

gene stability measure M
 average pairwise variation V of a gene with all other genes



geNorm

- automated analysis
 - ranking of candidate reference genes according to their stability
 - determination of how many genes are required for reliable normalization




http://medgen.ugent.be/genorm



geNorm

ranking of candidate reference genes according to their stability





calculation of the normalization factor

• geometric mean of 3 reference gene expression levels

geometric mean =
$$(a \times b \times c)^{1/3}$$

arithmetic mean = $\frac{a + b + c}{3}$


- controls for outliers
- compensates for differences in expression level between the reference genes





geNorm validation (I)


robust – insensitive to outliers





geNorm validation (II)


 purpose of normalization: reduction of non-specific variation only geNorm best reference genes are able to reduce most of the variation





geNorm validation (III)

 cancer patients survival curve statistically more significant results



log rank statistics NF4

0.003

NF1


0.006 0.021 0.023 0.056

Hoebeeck et al., Int J Cancer, 2006




geNorm validation (IV)


 mRNA haploinsufficiency measurements accurate assessment of small expression differences








- multiple reference gene normalisation has become common practice:
 - > 1000 citations of our geNorm technology in PubMed
 - > 6000 geNorm downloads worldwide
 - 3rd London qPCR Symposium survey / EMBO 2005 qPCR course







selection of stable reference genes

other approaches

- Global Pattern Recognition (Akilesh et al., Genome Research, 2003)
- BestKeeper (Pfaffl et al., Biotechnology Letters, 2004)
- Equivalence test (Haller et al., Analytical Biochemistry, 2004)
- ANOVA test (Brunner et al., BMC Plant Biology, 2004)
- Normfinder (Andersen et al., Cancer Research, 2004)
- Szabo et al., Genome Biology, 2004
- Abruzzo et al., Biotechniques, 2005 present mathematical (linear mixed-effects) models to analyze candidate reference genes $\log yij = \mu + Ti + Gj + \epsilon ij$
- Vandesompele, Kubista & Pfaffl
 Reference gene validation software for improved normalization
 in "Real-time PCR: an essential guide" (Horizon Bioscience, 2nd edition, 2009)





impact of RNA quality on expression stability

differences in reference gene ranking between intact and degraded RNA

Step*	Degraded RNA (CRS samples)	Intact RNA (CRS samples)	Degraded RNA (NP samples)	Intact RNA (NP samples)
1	HPRTI	GAPD	HPRT1	YWHAZ
2	YWHAZ	YWHAZ	ACTB	B2M
3	B2M	RPL3IA	RPL3IA	RPL3IA
4	TBP	B2M	GAPD	UBC
5	RPL3IA	UBC	TBP	GAPD
6	UBC	HPRT1	YWHAZ	HMBS
7	ACTB	TBP	HMBS	HPRT1
8	GAPD	ACTB	SDHA	SDHA
9	HMBS- SDHA	HMBS- SDHA	B2M- UBc	ACTB- TBP




new strategies for normalization

- need for something new rethink
 - reference gene validation requires (extensive) experimental work
 - sometimes not possible (lack of sample material, funding, time or devotion)
- there must be something better
 - EAR normalization (Expressed Alu Repeat)
 "using a repetitive sequence in the human transcriptome as a measure for the mRNA fraction"



EAR normalization - principle



rationale: repeat sequences are present in the UTR of many genes, and the differential expression of a small number of genes won't influence the overall repeat abundance in the transcriptome




Alu repeat elements

- by far the most abundant repeats in the human genome
- 1 million copies (10% of the genome), 31 subfamilies (well conserved)
- short interspersed elements (SINE) replicating via retrotransposition
- ~280 bp long, followed by a variable poly-A tail
- no known biological function
- implicated in human disease (unequal recombination)





Alu repeat element sequence conservation





in silico transcriptome analysis


- extraction of all Alu repeat elements in the human genome
 - UCSC genome browser table function
- database with repeat element info and gene structure information for all human genes -> 'expressed Alu repeats'
 - MySQL
- Alu subfamily sequence alignment
 - PHP script 'Alu FASTA generator'
 - wEMBOSS clustalW alignment
- primer design
- roughly 1500 human genes contain one or more Alu repeats

AluSx	532
AluJo	250
AluJb	236
AluSq	178
AluY	169
AluSg	161
FLAM_C	102



examples Alu containing genes

ADAMTS4 (1q23.3)



ADCY6 (12q13.12)






Alu repe

Alu repeat assay evaluation


AluSx assay (AluSq | AluJ)





EAR normalization


comparison of Alu repeat levels and NF based on 3 best reference genes
 Pearsons correlation 0.943 (p=0.0014)






EAR normalization

MYCN expression levels normalized by Alu repeat or NF3





geNorm ranking of candidate reference genes






conclusions Alu repeat normalization

- simple and convenient normalization strategy for
 - gene expression analysis (cDNA) (EAR normalization)
 - gene copy number quantification (DNA)
- no (extensive) experimental validation required
- only limited sample amount required
- strategy could be expanded to other expressed repeats in other organisms



problem of data-analysis

extraction of meaningful biological information from qPCR data




1 Well Threshold Cycle Ct Set Point Identifier 2 A5 24 normal ctrl 3 A6 23.8 normal ctrl 4 B5 24.1 normal ctrl 5 B6 23.5 normal ctrl 6 C5 25.6 patient 1 7 C6 25.5 patient 1 8 C11 N/A N/A 9 C12 N/A N/A 10 D5 24.7 patient 1 11 D6 25.3 patient 1 12 E5 24.9 patient 2 13 E6 25.3 patient 2 14 F5 25.4 patient 2 15 F6 25.4 patient 2 16 G5 28.9 deletion ctrl 18 H5 29.4 deletion ctrl 19 H6 29.3 deletion ctrl 20 A					_	
2 A5 24 normal ctrl 3 A6 23.8 normal ctrl 4 B5 24.1 normal ctrl 5 B6 23.5 normal ctrl 6 C5 25.6 patient 1 7 C6 25.5 patient 1 8 C11 N/A Patient 1 9 C12 N/A Patient 1 10 D5 24.7 patient 1 11 D6 25.3 patient 2 12 E5 24.9 patient 2 13 E6 25.3 patient 2 14 F5 25.4 patient 2 15 F6 25.4 patient 2 16 G5 28.9 deletion ctrl 18 H5 29.4 deletion ctrl 19 H6 29.3 deletion ctrl 19 H6 29.3 deletion ctrl 20 A1 24.6 nor		A	В		С	D
3 A6 23.8 normal ctrl 4 B5 24.1 normal ctrl 6 C5 25.6 patient 1 7 C6 25.5 patient 1 8 C11 N/A 9 C12 N/A 10 D5 24.7 patient 1 11 D6 25.3 patient 1 12 E5 24.9 patient 2 13 E6 25.3 patient 2 14 F5 25.4 patient 2 15 F6 25.4 patient 2 16 G5 28.9 deletion ctrl 17 G6 29.1 deletion ctrl 18 H5 29.4 deletion ctrl 19 H6 29.3 deletion ctrl 19 H6 29.3 deletion ctrl 20 A1 24.6 normal ctrl 21 A2 24.6 normal ctrl 22<			Threshold Cycle		Set Point	
4 B5 24.1 normal ctrl 5 B6 23.5 normal ctrl 6 C5 25.6 patient 1 7 C6 25.5 patient 1 8 C11 N/A 9 C12 N/A 10 D5 24.7 patient 1 11 D6 25.3 patient 1 12 E5 24.9 patient 2 13 E6 25.4 patient 2 14 F5 25.4 patient 2 15 F6 25.4 patient 2 16 G5 28.9 deletion ctrl 17 G6 29.1 deletion ctrl 18 H5 29.4 deletion ctrl 19 H6 29.3 deletion ctrl 19 H6 29.3 deletion ctrl 20 A1 24.6 normal ctrl 21 A2 24.6 normal ctrl 22 A11 N/A 23 A12 N/A 24 B1 24.2 normal ctrl 25 B2 24 normal ctrl 26 C1 24.5 patient 1 29 D2 24.9 patient 1 20 D1 25.7 patient 1 20 D1 25.7 patient 1 21 D2 D1 25.7 patient 1 22 D1 25.7 patient 1 23 D1 25.7 patient 1 24 D1 25.8 patient 1 25 D1 25.7 patient 1 26 D1 25.7 patient 1 27 C2 24.9 patient 2 28 D1 25.7 patient 1 29 D2 24.9 patient 2 29 D2 24.9 patient 2 30 E1 25.8 patient 2 31 E2 25.8 patient 2 31 E2 27 patient 2 32 F1 25.8 patient 2 33 F2 7 patient 2						
5 B6 23.5 normal ctrl 6 C5 25.6 patient 1 7 C6 25.5 patient 1 8 C11 N/A 9 C12 N/A 10 D5 24.7 patient 1 11 D6 25.3 patient 1 12 E5 24.9 patient 2 13 E6 25.3 patient 2 14 F5 25.4 patient 2 15 F6 25.4 patient 2 15 F6 25.4 patient 2 16 G5 28.9 deletion ctrl 17 G6 29.1 deletion ctrl 18 H5 29.4 deletion ctrl 19 H6 29.3 deletion ctrl 20 A1 24.6 normal ctrl 21 A2 24.6 normal ctrl 22 A11 N/A N/A 23				كانتكاك		
6 C5	-					
7 C6 25.5 patient 1 8 C11 N/A 9 C12 N/A 10 D5 24.7 patient 1 11 D6 25.3 patient 1 12 E5 24.9 patient 2 13 E6 25.3 patient 2 14 F5 25.4 patient 2 15 F6 25.4 patient 2 16 G5 28.9 deletion ctrl 17 G6 29.1 deletion ctrl 18 H5 29.4 deletion ctrl 19 H6 29.3 deletion ctrl 19 H6 29.3 deletion ctrl 20 A1 24.6 normal ctrl 21 A2 24.6 normal ctrl 22 A11 N/A 23 A12 N/A 24 B1 24.2 normal ctrl 25 B2 24 normal ctrl 26 C1 24.5 patient 1 27 C2 24.5 patient 1 29 D2 24.9 patient 1 29 D2 24.9 patient 1 20 C1 26.3 patient 1 20 D1 25.7 patient 1 21 D2						
8 C11 N/A 9 C12 N/A 10 D5 24.7 patient 1 11 D6 25.3 patient 2 13 E6 25.3 patient 2 14 F5 25.4 patient 2 15 F6 25.4 patient 2 16 G5 28.9 deletion ctrl 17 G6 29.1 deletion ctrl 18 H5 29.4 deletion ctrl 19 H6 29.3 deletion ctrl 19 H6 29.3 deletion ctrl 21 A2 24.6 normal ctrl 22 A11 N/A 23 A12 N/A 24 B1 24.2 normal ctrl 25 B2 24 normal ctrl 26 C1 24.5 patient 1 27 C2 24.5 patient 1 29 D2 24.9 patient 1 29 D2 24.9 patient 1 20 C1 25.7 patient 1 20 C2 24.9 patient 1 21 C2 24.9 patient 1 22 C3 1 Patient 1 23 C4 Patient 1 24 Patient 1 25 Patient 1 26 C1 24.5 patient 1 27 C2 24.5 patient 1 28 D1 25.7 patient 1 29 D2 24.9 patient 2 30 E1 26.4 patient 2 31 E2 26.4 patient 2 32 F1 25.8 patient 2 33 F2 7 patient 2 34 G1 28.8 deletion ctrl						
9 C12 N/A 10 D5 24.7 patient 1 11 D6 25.3 patient 1 12 E5 24.9 patient 2 13 E6 25.3 patient 2 14 F5 25.4 patient 2 15 F6 25.4 patient 2 16 G5 28.9 deletion ctrl 17 G6 29.1 deletion ctrl 18 H5 29.4 deletion ctrl 19 H6 29.3 deletion ctrl 19 H6 29.3 deletion ctrl 21 A2 24.6 normal ctrl 22 A11 N/A 23 A12 N/A 24 B1 24.2 normal ctrl 25 B2 24 normal ctrl 26 C1 24.5 patient 1 27 C2 24.5 patient 1 28 D1 25.7 patient 1 29 D2 24.9 patient 2 30 E1 26.4 patient 2 31 E2 26.4 patient 2 31 E2 27 patient 2 32 F1 25.8 patient 2 33 F2 7 patient 2 34 G1 28.8 deletion ctrl						patient 1
10 D5 24.7 patient 1 11 D6 25.3 patient 1 12 E5 24.9 patient 2 13 E6 25.3 patient 2 14 F5 25.4 patient 2 15 F6 25.4 patient 2 16 G5 28.9 deletion ctrl 17 G6 29.1 deletion ctrl 18 H5 29.4 deletion ctrl 19 H6 29.3 deletion ctrl 20 A1 24.6 normal ctrl 20 A1 24.6 normal ctrl 21 A2 24.6 normal ctrl 22 A11 N/A N/A 23 A12 N/A normal ctrl 24 B1 24.2 normal ctrl 25 B2 24 normal ctrl 26 C1 24.5 patient 1 27 C2 24.5 <						
11 D6 25.3 patient 1 12 E5 24.9 patient 2 13 E6 25.3 patient 2 14 F5 25.4 patient 2 15 F6 25.4 patient 2 16 G5 28.9 deletion ctrl 17 G6 29.1 deletion ctrl 18 H5 29.4 deletion ctrl 19 H6 29.3 deletion ctrl 20 A1 24.6 normal ctrl 21 A2 24.6 normal ctrl 22 A11 N/A 23 A12 N/A 24 B1 24.2 normal ctrl 25 B2 24 normal ctrl 26 C1 24.5 patient 1 27 C2 24.5 patient 1 29 D2 24.9 patient 1 29 D2 24.9 patient 1 29 D2 24.9 patient 1 20 C2 24.5 patient 1 21 C2 25.8 patient 1 22 C3 1 patient 1 23 C4 patient 1 24 D1 25.7 patient 1 25 D1 25.7 patient 1 26 D1 25.7 patient 1 27 C2 24.9 patient 1 28 D1 25.7 patient 1 29 D2 24.9 patient 2 30 E1 26.4 patient 2 31 E2 26.4 patient 2 32 F1 25.8 patient 2 33 F2 27 patient 2 34 G1 28.8 deletion ctrl	9					
12 E5 24.9 patient 2 13 E6 25.3 patient 2 14 F5 25.4 patient 2 15 F6 25.4 patient 2 16 G5 28.9 deletion ctrl 17 G6 29.1 deletion ctrl 18 H5 29.4 deletion ctrl 19 H6 29.3 deletion ctrl 20 A1 24.6 normal ctrl 20 A1 24.6 normal ctrl 21 A2 24.6 normal ctrl 22 A11 N/A normal ctrl 23 A12 N/A normal ctrl 24 B1 24.2 normal ctrl 25 B2 24 normal ctrl 26 C1 24.5 patient 1 27 C2 24.5 patient 1 29 D2 24.9 patient 1 29 D2 24.9	10					patient 1
13 E6 25.3 patient 2 14 F5 25.4 patient 2 15 F6 25.4 patient 2 16 G5 28.9 deletion ctrl 17 G6 29.1 deletion ctrl 18 H5 29.4 deletion ctrl 19 H6 29.3 deletion ctrl 20 A1 24.6 normal ctrl 21 A2 24.6 normal ctrl 22 A11 N/A N/A 23 A12 N/A N/A 24 B1 24.2 normal ctrl 25 B2 24 normal ctrl 25 B2 24 normal ctrl 25 B2 24 normal ctrl 26 C1 24.5 patient 1 27 C2 24.5 patient 1 29 D2 24.9 patient 1 29 D2 24.9 patient	11	D6		25.3		patient 1
14 F5 25.4 patient 2 15 F6 25.4 patient 2 16 G5 28.9 deletion ctrl 17 G6 29.1 deletion ctrl 18 H5 29.4 deletion ctrl 19 H6 29.3 deletion ctrl 20 A1 24.6 normal ctrl 21 A2 24.6 normal ctrl 22 A11 N/A N/A 23 A12 N/A N/A 24 B1 24.2 normal ctrl 25 B2 24 normal ctrl 25 B2 24 normal ctrl 25 B2 24 patient 1 26 C1 24.5 patient 1 27 C2 24.5 patient 1 28 D1 25.7 patient 1 29 D2 24.9 patient 2 30 E1 26.4 patient 2	12	E5		24.9		patient 2
15 F6 25.4 patient 2 16 G5 28.9 deletion ctrl 17 G6 29.1 deletion ctrl 18 H5 29.4 deletion ctrl 19 H6 29.3 deletion ctrl 20 A1 24.6 normal ctrl 21 A2 24.6 normal ctrl 22 A11 N/A 23 A12 N/A 24 B1 24.2 normal ctrl 25 B2 24 normal ctrl 26 C1 24.5 patient 1 27 C2 24.5 patient 1 28 D1 25.7 patient 1 29 D2 24.9 patient 1 30 E1 26.3 patient 2 31 E2 26.4 patient 2 32 F1 25.8 patient 2 33 F2 27 patient 2 34 <td>13</td> <td>E6</td> <td></td> <td>25.3</td> <td></td> <td>patient 2</td>	13	E6		25.3		patient 2
16 G5 28.9 deletion ctrl 17 G6 29.1 deletion ctrl 18 H5 29.4 deletion ctrl 19 H6 29.3 deletion ctrl 20 A1 24.6 normal ctrl 21 A2 24.6 normal ctrl 22 A11 N/A 23 A12 N/A 24 B1 24.2 normal ctrl 25 B2 24 normal ctrl 26 C1 24.5 patient 1 27 C2 24.5 patient 1 28 D1 25.7 patient 1 29 D2 24.9 patient 1 29 D2 24.9 patient 2 31 E2 26.4 patient 2 32 F1 25.8 patient 2 33 F2 27 patient 2 34 G1 28.8 deletion ctrl	14	F5		25.4		patient 2
17 G6 29.1 deletion ctrl 18 H5 29.4 deletion ctrl 19 H6 29.3 deletion ctrl 20 A1 24.6 normal ctrl 21 A2 24.6 normal ctrl 22 A11 N/A 23 A12 N/A 24 B1 24.2 normal ctrl 25 B2 24 normal ctrl 26 C1 24.5 patient 1 27 C2 24.5 patient 1 28 D1 25.7 patient 1 29 D2 24.9 patient 1 29 D2 24.9 patient 2 30 E1 26.3 patient 2 31 E2 26.4 patient 2 32 F1 25.8 patient 2 33 F2 7 patient 2 34 G1 28.8 deletion ctrl	15	F6		25.4		patient 2
18 H5 29.4 deletion ctrl 19 H6 29.3 deletion ctrl 20 A1 24.6 normal ctrl 21 A2 24.6 normal ctrl 22 A11 N/A 23 A12 N/A 24 B1 24.2 normal ctrl 25 B2 24 normal ctrl 26 C1 24.5 patient 1 27 C2 24.5 patient 1 28 D1 25.7 patient 1 29 D2 24.9 patient 1 29 D2 24.9 patient 2 30 E1 26.3 patient 2 31 E2 26.4 patient 2 32 F1 25.8 patient 2 34 G1 28.8 deletion ctrl	16	G5		28.9		deletion ctrl
19 H6 29.3 deletion ctrl 20 A1 24.6 normal ctrl 21 A2 24.6 normal ctrl 22 A11 N/A 23 A12 N/A 24 B1 24.2 normal ctrl 25 B2 24 normal ctrl 26 C1 24.5 patient 1 27 C2 24.5 patient 1 28 D1 25.7 patient 1 29 D2 24.9 patient 1 30 E1 26.3 patient 2 31 E2 26.4 patient 2 32 F1 25.8 patient 2 33 F2 27 patient 2 34 G1 28.8 deletion ctrl	17	G6		29.1		deletion ctrl
20 A1 24.6 normal ctrl 21 A2 24.6 normal ctrl 22 A11 N/A N/A 23 A12 N/A normal ctrl 24 B1 24.2 normal ctrl 25 B2 24 normal ctrl 26 C1 24.5 patient 1 27 C2 24.5 patient 1 28 D1 25.7 patient 1 29 D2 24.9 patient 1 30 E1 26.3 patient 2 31 E1 26.4 patient 2 32 F1 25.8 patient 2 33 F2 27 patient 2 34 G1 28.8 deletion ctrl	18	H5		29.4		deletion ctrl
21 A2 24.6 normal ctrl 22 A11 N/A normal ctrl 23 A12 N/A normal ctrl 24 B1 24.2 normal ctrl 25 B2 24 normal ctrl 26 C1 24.5 patient 1 27 C2 24.5 patient 1 28 D1 25.7 patient 1 29 D2 24.9 patient 1 30 E1 26.3 patient 2 31 E2 26.4 patient 2 32 F1 25.8 patient 2 33 F2 27 patient 2 34 G1 28.8 deletion ctrl	19	H6		29.3		deletion ctrl
22 A11 N/A 23 A12 N/A 24 B1 24.2 normal ctrl 25 B2 24 normal ctrl 26 C1 24.5 patient 1 27 C2 24.5 patient 1 28 D1 25.7 patient 1 29 D2 24.9 patient 1 30 E1 26.3 patient 2 31 E2 26.4 patient 2 32 F1 25.8 patient 2 33 F2 27 patient 2 34 G1 28.8 deletion ctrl	20	A1		24.6		normal ctrl
23 A12 N/A 24 B1 24.2 normal ctrl 25 B2 24 normal ctrl 26 C1 24.5 patient 1 27 C2 24.5 patient 1 28 D1 25.7 patient 1 29 D2 24.9 patient 1 30 E1 26.3 patient 2 31 E2 26.4 patient 2 32 F1 25.8 patient 2 33 F2 27 patient 2 34 G1 28.8 deletion ctrl	21	A2		24.6		normal ctrl
24 B1 24.2 normal ctrl 25 B2 24 normal ctrl 26 C1 24.5 patient 1 27 C2 24.5 patient 1 28 D1 25.7 patient 1 29 D2 24.9 patient 1 30 E1 26.3 patient 2 31 E2 26.4 patient 2 32 F1 25.8 patient 2 33 F2 27 patient 2 34 G1 28.8 deletion ctrl	22	A11		N/A		
25 B2 24 normal ctrl 26 C1 24.5 patient 1 27 C2 24.5 patient 1 28 D1 25.7 patient 1 29 D2 24.9 patient 1 30 E1 26.3 patient 2 31 E2 26.4 patient 2 32 F1 25.8 patient 2 33 F2 27 patient 2 34 G1 28.8 deletion ctrl	23	A12		N/A		
26 C1 24.5 patient 1 27 C2 24.5 patient 1 28 D1 25.7 patient 1 29 D2 24.9 patient 1 30 E1 26.3 patient 2 31 E2 26.4 patient 2 32 F1 25.8 patient 2 33 F2 27 patient 2 34 G1 28.8 deletion ctrl	24	B1		24.2		normal ctrl
27 C2 24.5 patient 1 28 D1 25.7 patient 1 29 D2 24.9 patient 1 30 E1 26.3 patient 2 31 E2 26.4 patient 2 32 F1 25.8 patient 2 33 F2 27 patient 2 34 G1 28.8 deletion ctrl	25	B2		24		normal ctrl
28 D1 25.7 patient 1 29 D2 24.9 patient 1 30 E1 26.3 patient 2 31 E2 26.4 patient 2 32 F1 25.8 patient 2 33 F2 27 patient 2 34 G1 28.8 deletion ctrl	26	C1		24.5		patient 1
29 D2 24.9 patient 1 30 E1 26.3 patient 2 31 E2 26.4 patient 2 32 F1 25.8 patient 2 33 F2 27 patient 2 34 G1 28.8 deletion ctrl	27	C2		24.5		patient 1
29 D2 24.9 patient 1 30 E1 26.3 patient 2 31 E2 26.4 patient 2 32 F1 25.8 patient 2 33 F2 27 patient 2 34 G1 28.8 deletion ctrl	28	D1		25.7		patient 1
30 E1 26.3 patient 2 31 E2 26.4 patient 2 32 F1 25.8 patient 2 33 F2 27 patient 2 34 G1 28.8 deletion ctrl	29	D2		24.9		
31 E2 26.4 patient 2 32 F1 25.8 patient 2 33 F2 27 patient 2 34 G1 28.8 deletion ctrl	30	E1		26.3		
32 F1 25.8 patient 2 33 F2 27 patient 2 34 G1 28.8 deletion ctrl	31	E2		26.4		
33 F2 27 patient 2 34 G1 28.8 deletion ctrl	32	F1		25.8		
34 G1 28.8 deletion ctrl	33	F2		27		
	34	G1		28.8		
	35	G2		29.6		



problem of data-analysis

extraction of meaningful biological information from qPCR data



					_	
	A	В	0.		C	D
1		Threshold Cycle	Ct	Set	Point	Identifier
2	A5		24			normal ctrl
3	A6		23.8			normal ctrl
4	B5		24.1			normal ctrl
5	B6		23.5			normal ctrl
6	C5		25.6			patient 1
7	C6		25.5			patient 1
8	C11		N/A			
9	C12		N/A			
10	D5		24.7			patient 1
11	D6		25.3			patient 1
12	E5		24.9			patient 2
13	E6		25.3			patient 2
14	F5		25.4			patient 2
15	F6		25.4			patient 2
16	G5		28.9			deletion ctrl
17	G6		29.1			deletion ctrl
18	H5		29.4			deletion ctrl
19	H6		29.3			deletion ctrl
20	A1		24.6			normal ctrl
21	A2		24.6			normal ctrl
22	A11		N/A			
23	A12		N/A			
24	B1		24.2			normal ctrl
25	B2		24			normal ctrl
26	C1		24.5			patient 1
27	C2		24.5			patient 1
28	D1		25.7			patient 1
29	D2		24.9			patient 1
30	E1		26.3			patient 2
31	E2		26.4			patient 2
32	F1		25.8			patient 2
33	F2		27			patient 2
34	G1		28.8			deletion ctrl
35	G2		29.6			deletion ctrl





data-analysis: 3 generations of quantification models

Livak and Schmittgen (2001)
 100% PCR efficiency, 1 reference gene

$$NRQ = 2^{\Delta\Delta Ct}$$


Pfaffl (2001)
 adjusted PCR efficiency, 1 ref. gene

$$NRQ = \frac{E_{goi}^{\Delta Ct, goi}}{E_{ref}^{\Delta Ct, ref}}$$

qBase model (2007)
 adjusted PCR efficiency & multiple reference genes

$$NRQ = rac{E_{goi}^{\Delta Ct,goi}}{\sqrt[n]{\prod_{i}^{n} E_{ref_{i}}^{\Delta Ct,ref_{i}}}}$$





universal quantification model with proper error propagation

R 19.12 Genome Biology 2007, Volume 8, Issue 2, Article R19 Hellemans et al.

$$s_{x,jl} = \sqrt{\frac{1}{h-1}\sum_{i=1}^{h} \left(Q_{qjl} - \overline{Q_{jl}}\right)^2}$$
 (formula 3)

$$SE(slope_{jl}) = \frac{s_{e,jl}}{s_{e,jl}(h-1)}$$
 (formula 4)

The base for exponential amplification E, and its standard error SE(E) are calculated from these values:

$$E_{+} = 10 \left(\frac{1}{\text{slope}_g} \right)$$
 (formula 5)

$$SE(E_{jl}) = \frac{E_{jl} \cdot ln(10) \cdot SE(slope_{jl})}{slope_{jl}}$$
 (formula 6)

Conversion of Cq values into relative quantities

Calculation of the average Cq value for all replicates of the same gene/sample combination jk within a given run l:

$$\frac{Cq_{jkl}}{Cq_{jkl}} = \frac{\sum\limits_{l=1}^{n} Cq_{ijkl}}{n} \qquad \qquad \text{(formula 7)}$$

$$SE\left(Cq_{jkl}\right) = \sqrt{\frac{1}{n(n-1)}\sum_{l=1}^{n}\left(Cq_{ijkl} - \overline{Cq_{jkl}}\right)^{2}}$$
 (formula 8)

Step 2

Transformation of mean Cq value into RQ using the gene specific PCR efficiency E_{sh} with minimization of the overall error:

$$Cq_{reference,jl} = \overline{Cq_{jl}} = \frac{\sum\limits_{k=1}^{s} Cq_{jkl}}{s}$$
 (formula 9)

 $\Delta Cq_{jkl} = Cq_{reference,jl} - Cq_{jkl}$ (formula 10)

$$RQ_{jkl} = E_{jl}^{\quad \delta Cq_{jkl}}$$
 (formula 11)

$$EE[RQ_{jkl}] + RQ_{jkl}^{q} \begin{bmatrix} \partial Cq_{jkl} SD(E_{f}) \\ E_{fl} \end{bmatrix}^{p} + (In(E_{f}) SD(\overline{Cq_{jkl}}))^{q}$$
 (formula tr

Normalization: inter-run calibration

The procedures for normalization and inter-run calibration are highly analogous and are therefore described in parallel. Step lCalculation of the normalization factor NF for sample k based on the RQs of the reference genes p.

http://genomebiology.com/2007/8/2/R15

Step I'

Calculation of the calibration factor CF for gene j in run l based on the NRQs of the IRCs m:

$$NF_k = \sqrt{\prod_{p=1}^f RQ_{pk}}$$
 (formula 13)

$$CF_{jl} = \sqrt{\prod_{m=1}^{c} NRQ_{jlm}}$$
 (formula 13'; for definition of NRQ ,

$$SE(NF_k) = NF_k \sqrt{\sum_{p=1}^{f} \left(\frac{SE(RQ_{pk})}{f \cdot RQ_{pk}} \right)^2}$$
 (formula 14)

$$E\left(CF_{\beta}\right) = CF_{\beta}\sqrt{\sum_{m=1}^{c}\left(\frac{SE\left(NRQ_{\beta m}\right)^{2}}{c\cdot NRQ_{\beta m}}\right)^{2}}$$
 (formula 14*)

Step 2 Conversion of RQs into NRQs.

Step 2' Conversion of NRQs into CNRQs:

$$NRQ_{jk} = \frac{RQ_{jk}}{NR}$$
 (formula 15)

$$CNRQ_{jkl} = \frac{NRQ_{jkl}}{CE}$$
 (formula 15')

$$SE[NRQ_{jk}] = NRQ_{jk} \sqrt{\frac{SE[NP_k]}{NP_k}} + \frac{SE[NQ_{jk}]}{RQ_{jk}}$$
 (formula 16)

$$SE(CNRQ_{jkl}) = CNRQ_{jkl} \sqrt{\frac{SE(CP_{jl})}{CP_{jl}}} \stackrel{d}{\rightarrow} + \frac{SE(NRQ_{jkl})}{NRQ_{jkl}} \stackrel{d}{\rightarrow}$$

Coefficient of variation of NRQs of a reference gene

Step 1

Calculation of the mean NRQ for all samples k and a given reference gene p:

$$\overline{NRQ_p} = \frac{\sum_{k=1}^{g} NRQ_{pk}}{s}$$
 (formula 17)

 $s_{e,\beta} = \sqrt{\frac{\sum\limits_{g \in \mathbb{N}} \left(Cl_{qql,measured} - Cl_{qql,predicted}\right)^2}{h - 2}}$ (formula 2)

R19.12 Genome Biology 2007, Volume 8, Issue 2, Article R19 Hellemans et al.

$$s_{x,jl} = \sqrt{\frac{1}{h-1}\sum_{l=1}^{h} \left(Q_{qll} - \overline{Q_{jl}}\right)^2}$$
 (formula 3)

$$SE(slope_{jl}) = \frac{s_{e,jl}}{s_{e,jl}(h-1)}$$
 (formula 4)

The base for exponential amplification E, and its standard error SE(E) are calculated from these values:

$$E_{jl} = 10^{\left[\frac{1}{2\log g}\right]}$$
 (formula 5)
 $SE[E_{i}] = E_{jl} \cdot ln(10) \cdot SE(slope_{jl})$ (formula 6)

Conversion of Cq values into relative quantities

Calculation of the average Cq value for all replicates of the same gene/sample combination jk within a given run l:

$$Cq_{jkl} = \frac{\sum_{i=1}^{m} -q_{ikl}}{n}$$
 (formula 7)
 $SE(Cq_{jkl}) = \frac{1}{n(m-1)}\sum_{i=1}^{n} (Q_{ijkl} - \overline{Q}_{jkl})^n$ (formula 8)

Step 2 Transformation of mean Cq value into RQ using the gene specific PCR efficiency E_{σ} with minimization of the overall error:

$$Cq_{reference,jl} = \overline{Cq_{jl}} = \frac{\sum\limits_{k=1}^{s} Cq_{jkl}}{s} \qquad \qquad \left(\text{ formula 9}\right)$$

$$\Delta Cq_{jkj} = Cq_{reference, jl} - Cq_{jkj}$$
 (formula 10)

$$RQ_{jkl} = E_{jl}^{\Delta Cq_{jkl}}$$
 (formula 11)

$M(M_{H}) = M_{H} \begin{bmatrix} & & & \\ & & & \\ & & & \end{bmatrix} + \{ (M(E_{f}) + M(M_{H}) \}$

The procedures for normalization and inter-run calibration are highly analogous and are therefore described in parallel. Step ICalculation of the normalization factor NF for sample k based on the RQs of the reference genes p.

http://genomebiology.com/2007/8/2/R19

Step 1°

Step I Calculation of the calibration factor CF for gene j in run I based on the NROs of the IRCs m:

$$NF_k = \sqrt{\prod_{p>3} RQ_{pk}}$$
 (formula 13)
 $CF_{jl} = \sqrt{\prod_{m=1}^{c} NRQ_{jlm}}$ (formula 13'; for definition of NRQ_{jlm})
see formula 15)

$$SE(NF_k) = NF_k \sqrt{\sum_{p=1}^{f} \left(\frac{SE(RQ_{pk})}{f \cdot RQ_{pk}}\right)^2}$$
 (formula 14)

$$SE(CF_{jl}) = CF_{jl}\sqrt{\sum_{m=1}^{C}\left(\frac{SE(NRQ_{jlm})}{c \cdot NRQ_{jlm}}\right)^{2}}$$
 (formula 14')

Step 2 Conversion of RQs into NRQs.

Step 2* Conversion of NROs into CNROs:

$$NRQ_{jk} = \frac{RQ_{jk}}{NF_k}$$
 (formula 15)

$$CNRQ_{jkl} = \frac{NRQ_{jkl}}{CF_n}$$
 (formula 15')

$$E(NRQ_A) = NRQ_A \sqrt{\frac{SE(NF_b)}{NF_b}^2 + \left(\frac{SE(RQ_A)}{RQ_A}\right)^2}$$
 (formula 16)

Coefficient of variation of NRQs of a reference gene Step I

Calculation of the mean NRQ for all samples k and a given reference gene p:

$$\frac{\sum_{k=1}^{s} NRQ_{pk}}{S}$$
 (formula 17)

Genome Biology 2007, 8:R19

Genome Biology 2007, 8:R19



qBase paper

Method

Open Access

qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data

Jan Hellemans, Geert Mortier, Anne De Paepe, Frank Speleman and Jo Vandesompele

Address: Center for Medical Genetics, Ghent University Hospital, De Pintelaan, B-9000 Ghent, Belgium.

Correspondence: Jo Vandesompele. Email: Joke.Vandesompele@UGent.be

Published: 9 February 2007

Genome Biology 2007, 8:R19 (doi:10.1186/gb-2007-8-2-r19)

The electronic version of this article is the complete one and can be found online at http://genomebiology.com/2007/8/2/R19

Received: 31 August 2006 Revised: 7 December 2006 Accepted: 9 February 2007

© 2007 Hellemans et al.; licensee BioMed Central Ltd.

This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Hellemans et al., Genome Biology, 2007

RethinkPCR Scientific Conferences, Europe


BIO RAD

qBasePlus


- based on Ghent University's geNorm and qBase technology
- up to fifty 384-well plates
- multiple reference genes for accurate normalization
- detection and correction of inter-run variation
- dedicated error propagation
- automated analysis; no manual interaction required
- basic version is free, available from Biogazelle (http://www.biogazelle.com)








run editor (Windows XP)







PCR efficiency correction and results (Windows Vista)







inter-run calibration (Suse Linux)





results in 24 seconds






RTPrimerDB 2003

- Nucleic Acids Research, Vol. 31, No. 1 122-123, 2003
- http://medgen.ugent.be/rtprimerdb
- database of experimentally validated real-time PCR assays
 - SYBR Green I (61%), TaqMan (38%), others (1%)
 - human (72%), mouse (16%), rat (10%), others (2%)
 - gene expression (97%), others (3%)
- standardization
- time saving



gene expression assay viewer








Assay Details

Application: Gene Expression Quantification/Detection GXP **Detection:** SYBR Green I

Template: cDNA

This primer pair amplifies part of the following transcript:



Forward Primer: CCGGGCATGATCTGCAA (17 bp)

Reverse Primer: CCGCCGAAGTAGAAGTCATCTT (22 bp)

Annealing Temperature: 60 °C

BLAST primers/probes





assay details (2)

Publication

PubMed ID: 12545167

Submitter's Remarks

primers in coding sequence of MYCN

Submitter

Jo Vandesompele (joke.vandesompele@ugent.be)

Ghent University Hospital, Center for Medical Genetics

De Pintelaan 185, 9000 Ghent, Oost-Vlaanderen, Belgium

http://medgen.ugent.be

Users' Feedback [login to add feedback]

13-SEP-05 - Filip Pattyn , Belgium - (filip.pattyn@ugent.be)

Melt curve: single peak | Agarose gel: correct band |

Amplification efficiency: 95% - 100% | Template: single sample cDNA | Number of dilution points: 4 | Dilution factor: 4-fold | Ct range: 25-31 | Correlation

coefficient: 0.999



RTPrimerDB update 2006

- Nucleic Acids Research, 2006, Vol. 34, D684-D688
- in silico assay evaluation pipeline
 - SNP or sequence errors
 - secondary structure analysis

D684–D688 Nucleic Acids Research, 2006, Vol. 34, Database issue doi:10.1093/nar/gkj155

RTPrimerDB: the real-time PCR primer and probe database, major update 2006

Filip Pattyn, Piet Robbrecht, Anne De Paepe, Frank Speleman and Jo Vandesompele*

Center for Medical Genetics Ghent (CMGG), Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium


Received September 15, 2005; Revised and Accepted October 31, 2005





Organism:	Homo sapiens	×	
Gene Symbol/Name:	PSAP	 Substring 	O Exact phrase
Gene ID:			
forward primer sequence	GGCTTTCCCGTGTC	TTCC	<u> </u>
reverse primer sequence	CTTCGGAGAGCTAG	CAGGTTACA	
probe 1 sequence			(optional)
probe 2 sequence			(optional)
Template	cDNA 💌		
Annealing temperature (°C)	60	(betwee	n 0 en 100)





In silico assay evaluation (step 2: sequence verification)

In silico assay ID: 237

Gene Information

PSAP: prosaposin (variant Gaucher disease and variant metachromatic leukodystrophy)

Organism: Homo sapiens (Hs, Human)

Entrez Gene ID: 5660

Assay Details

Template: cDNA

Annealing Temperature: 60 °C

Sequence Evaluation

Forward Primer:

your forward primer: GGCTTTCCCGTGTCTTTCC (19 bp) perfect match with reference sequence

SNPs: none detected

Reverse Primer:

your reverse primer: CTTCGGAGAGCTAGCAGGTTACA (23 bp) perfect match with reference sequence

SNPs: none detected


BLAST primers/probes

Alignment attempts on 2 PSAP transcript variants:

ENST00000357471: alignment succesfull ENST00000360237: alignment succesfull

Change input

proceed







In silico assay evaluation (step 3: assay viewer)

In silico assay ID: 237

Gene Information

PSAP: prosaposin (variant Gaucher disease and variant metachromatic leukodystrophy)

Organism: Homo sapiens (Hs, Human)


Entrez Gene ID: 5660

Assay Details

Template: cDNA

Annealing Temperature: 60 °C

This primer pair amplifies part of the following transcripts:








- unafold
- Zuker et al., Nucleic Acids Research, 2003


mfold results					
RTPrimerDB ID: 8, Ensembl transcript ID: ENST00000339647					
Temperature (°C)	60 (between 0 en 100)				
Mg concentration (mM)	3	(≤ 100)			
Na Concentration (mM)	50	(≥ 10) and (≤ 300 if Mg conc is > 0)			
	also show secondary structures outside primer annealing regions				
also show secondary structures with positive energy					
Refold					
No significant secondary structure where primers anneal					









































new features 2008

- all NCBI organisms
- RDML compliant
- primer design pipeline
 - primer3
 - high-throughput



RDML (www.rdml.org)



Contact : info@rdml.org © 2008 RDML Consortium



• European Biotechnology News, Issue 03-04/2008

40 Euro Biotech News Nº 1-2 | Volume 7 | 2008

TECHNOLOGY

News

Barcoding update

Constance – GATC Biotech has developed a platform-independent barcoding system that allows an additional level of parallel processing with a virtually unlimited increase in the number of samples processed. GATC's system is suitable for use with the Roche GS FLX and Illumina Genome PCR

A new standard for qPCR data: RDML

Andreas Untergasser, Wageningen University, and Jo Vandesompele, Univ. Ghent



RDML

- Nature Biotechnology (submitted)
- http://www.mibbi.org
 Promoting coherent minimum reporting requirements for biological and biomedical investigations: The MIBBI project

Chris F Taylor^{1,2,*}, Dawn Field^{2,3,*}, Susanna-Assunta Sansone^{1,2,*}, Jan Aerts⁴, Rolf Apweiler¹, Michael Ashburner⁵, Catherine A Ball⁶, Pierre-Alain Binz^{7,8}, Molly Bogue⁹, Tim Booth², Alvis Brazma¹, Ryan R Brinkman¹⁰, Adam Michael Clark¹¹, Eric W Deutsch¹², Oliver Fiehn¹³, Jennifer Fostel¹⁴, Peter Ghazal¹⁵, Frank Gibson¹⁶, Tanya Gray^{2,3}, Graeme Grimes¹⁵, John M Hancock¹⁷, Nigel W Hardy¹⁸, Henning Hermjakob¹, Randall K Julian, Jr.¹⁹, Matthew Kane²⁰, Carsten Kettner²¹, Christopher Kinsinger²², Eugene Kolker^{23,24}, Martin Kuiper^{25a,b,e}, Nicolas Le Novère¹, Jim Leebens-Mack²⁶, Suzanna E Lewis²⁷, Phillip Lord¹⁶, Ann-Marie Mallon¹⁷, Nishanth Marthandan²⁸, Hiroshi Masuya²⁹, Ruth McNally³⁰, Alexander Mehrle³¹, Norman Morrison^{2,32}, Sandra Orchard¹, John Quackenbush³³, James M Reecy³⁴, Donald G Robertson³⁵, Philippe Rocca-Serra^{1,36}, Henry Rodriguez²², Heiko Rosenfelder³¹, Javier Santoyo-Lopez¹⁵, Richard H Scheuermann²⁸, Daniel Schober¹, Barry Smith³⁷, Jason Snape³⁸, Chris J Stoeckert³⁹, Keith Tipton⁴⁰, Peter Sterk¹, Andreas Untergasser⁴¹, Jo Vandesompele⁴², Stefan Wiemann³¹





general conclusions

- rethinking is useful
- validation matters
- reference gene validation is mandatory
- advanced quantification models and proper software enable accurate and precise results
- RTPrimerDB enables straightforward and automated qPCR assay quality control





- Jo Vandesompele (geNorm)
- Jan Hellemans (qBase)
- Filip Pattyn (RTPrimerDB)
- Jasmien Hoebeeck
- Katleen De Preter
- Nurten Yigit
- Frank Speleman
- Rob Powel
- Stephen Bustin, Michael Pfaffl, Vladimir Benes









